NASDAQ · RLMD
Relmada Therapeutics, Inc.
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
Loading market information…
NASDAQ · ACRV · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acrivon Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 50.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Acrivon Therapeutics, Inc. Common Stock’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.45. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acrivon Therapeutics, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 14, 2025 |
| -$0.51+10.53% vs estimate |
| $0.00 |
| Q4 2024 | Mar 27, 2025 | -$0.60+13.04% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.59-5.36% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
10 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.44+$0.09 (+2.69%)
Relmada Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 57.0% below the high.
$2.65$0.00 (0.0%)
Repare Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$7.80-$0.19 (-2.32%)
Immunic, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.28% below the high.
$3.81+$0.05 (+1.33%)
Unicycive Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.41% below the high.
$0.43+$0.02 (+4.66%)
Vaxart, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.17% below the high.
$1.35-$0.06 (-4.26%)
Cibus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.79% below the high.
$1.35-$0.03 (-2.17%)
PMV Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.32% below the high.
$0.62-$0.02 (-3.84%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
